ArticleScientific reports2025
Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vasodilatory and neuroprotective properties of felodipine were characterized in normal and ischemic rabbit eyes, an ocular hypertension (OHT) rat model, and cultured human neuron-like cells. Blood flow in the optic nerve head (ONH) was measured using laser speckle flowgraphy following intravitreally injected felodipine into normal and ischemic rabbit eyes receiving endothelin-1 injection. Felodipine concentrations in the retina-choroidal tissue were determined using mass spectrometry, and ocular safety was assessed using in-life examinations and histopathology in rabbits. The number of retinal ganglion cells (RGCs) was counted following intravitreal felodipine injection in hypertonic saline-induced OHT rats. The in vitro neuroprotective effects of felodipine against vincristine-induced nuclear loss and neurite shortening were evaluated in differentiated SH-SY5Y neuron-like cells. Felodipine increased ONH blood flow in a dose-dependent manner in normal rabbit eyes. High felodipine dosage (780 nmol/eye) improved blood circulation in endothelin-1-induced ischemic eyes. The ONH blood flow response to felodipine correlated with tissue concentration-time profiles. Even high dose of felodipine did not cause any ocular toxicity. Furthermore, felodipine protected SH-SY5Y cells against vincristine-induced damage and prevented OHT-induced RGC cell loss following its administration (40 nmol/eye). Felodipine can act as a neuroprotectant against glaucomatous neuropathy via improved ONH microcirculation and direct neuroprotection of RGCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.